Montelukast Milpharm

Montelukast, the active ingredient in Montelukast Milpharm, is a leukotriene receptor antagonist presented as an oral formulation for oral use. It is used to manage asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children as prescribed by a healthcare professional.

GNH USA supplies Montelukast Milpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to reduce airway inflammation and bronchoconstriction. - Asthma (maintenance therapy): improves long‑term control and reduces exacerbations. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort. - Nausea: transient gastrointestinal upset. - Dizziness: occasional light‑headedness. - Fatigue: mild tiredness. - Cough: non‑productive.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips or tongue. - Stevens‑Johnson syndrome: severe skin reactions. - Hepatic injury: elevated liver enzymes. - Anaphylaxis: life‑threatening allergic response. - Mood changes: depression or anxiety. - Suicidal thoughts: rare neuropsychiatric events.

Before initiating therapy, consider the following safety measures. - Assess liver function: monitor hepatic enzymes in patients with liver disease. - Monitor neuropsychiatric symptoms: watch for mood changes or suicidal ideation. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Use with caution with enzyme inducers: phenobarbital may reduce efficacy. - Store at room temperature: keep in the original pack, protect from moisture.

Montelukast may interact with several medicines; categorize the risk level.

Major Interactions (Avoid): - Ritonavir: may increase montelukast plasma concentrations. - Phenobarbital: may reduce montelukast effectiveness. - Carbamazepine: may lower drug exposure.

Moderate Interactions (Monitor Closely): - Fluconazole: may raise montelukast levels. - Warfarin: potential alteration of INR values. - Beta‑agonists: additive bronchodilatory effect may require dose adjustment.